retatrutide safety trial results produces up to 30.3% weight loss in Phase 3 Lilly's triple agonist achieves 16.8%

The exact mechanism isn't fully understood, but the additional 5-7% weight loss demonstrates GIP's independent contribution beyond GLP-1 alone

doi: 10.1038/npp.2014.74 32 AlhadeffALRupprechtLEHayesMR

Glucagon-Like Peptide-1, a natural hormone that regulates insulin and appetite

The absence of water in this form dramatically reduces the chemical reactions that cause peptide degradation

This ensures the treatment is only supplied if it is considered safe and appropriate by a qualified independent prescriber

A 2025 study on liraglutide nanoparticles demonstrated successful transdermal delivery with sustained effects in early-stage testing